Reviewing SI-Bone (NASDAQ:SIBN) & Avinger (NASDAQ:AVGR)
Avinger (NASDAQ:AVGR) and SI-Bone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
Volatility & Risk
Avinger has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, SI-Bone has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
This table compares Avinger and SI-Bone’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avinger||$9.13 million||0.94||-$19.45 million||($3.18)||-0.09|
|SI-Bone||$67.30 million||6.59||-$38.40 million||($1.55)||-10.07|
Avinger has higher earnings, but lower revenue than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Avinger and SI-Bone, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Avinger currently has a consensus price target of $1.40, suggesting a potential upside of 381.60%. SI-Bone has a consensus price target of $23.60, suggesting a potential upside of 51.19%. Given Avinger’s higher probable upside, research analysts clearly believe Avinger is more favorable than SI-Bone.
Institutional & Insider Ownership
7.1% of Avinger shares are held by institutional investors. Comparatively, 48.8% of SI-Bone shares are held by institutional investors. 0.5% of Avinger shares are held by insiders. Comparatively, 38.8% of SI-Bone shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Avinger and SI-Bone’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
SI-Bone beats Avinger on 11 of the 14 factors compared between the two stocks.
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.